Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

You are reading 1 of 2 free-access articles allowed for 30 days

Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

By Mindo - 07/6/21 1:30 PM | 88 views

Priscilla Lynch presents a round-up of some of the most topical research presented at this year’s ASCO Annual Meeting

Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type of kidney cancer, clear-cell renal carcinoma (RCC). A phase 3 international study, presented at the 2021 ASCO Annual Meeting, found that pembrolizumab could offer an effective treatment for patients currently with few other options.

KEYNOTE-564 is the first phase 3 study with a checkpoint inhibitor in the adjuvant setting to improve DFS for patients with high risk fully resected RCC. “Despite surgery, recurrence is common in clear-cell renal cell carcinoma, and should it recur, there are limited curative treatment options for patients. Given the success of pembrolizumab in the KEYNOTE-564 trial, this population may soon have a new standard of care,” said ASCO Chief Medical Officer and Executive Vice President Dr Julie R. Gralow.

At the study’s first interim analysis with 24 months median follow-up, the risk of disease recurrence or death was reduced by 32 per cent compared with placebo. The 24-month estimated DFS rate was 77.3 per cent with pembrolizumab, compared to 68.1 per cent with placebo. Overall, DFS benefit was consistent across subgroups.
The estimated preliminary OS rate at 24 months was 96.6 per cent with pembrolizumab and 93.5 per cent with placebo.
Grade 3-5 all-cause adverse events (AEs) were more common with pembrolizumab than placebo – 32.4 per cent versus 17.7 per cent with placebo, respectively. No treatment-related deaths occurred in the pembrolizumab arm.

“Pembrolizumab may provide a promising treatment for patients for whom there are few therapy options. KEYNOTE-564’s disease-free survival supports pembrolizumab as a potential new standard of care in the adjuvant setting to delay disease recurrence for patients with fully resected clear cell RCC,” said lead author Dr Tony Choueiri, who heads the Lank Centre for Genitourinary Oncology at the Dana Farber Cancer Institute.

Leave a Reply

Latest
Latest Issue
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read